CLAIM #22776 · EMR (EMR) · 2024Q4 earnings call · Nov 5, 2024 · due Sep 30, 2025
“we're confident that Test & Measurement will see continued momentum going into 2025.”
Ram Krishnan · COO
In context
“g on the approval process for projects. Did you see any of that? And then just separately, what's going into the assumptions about the second half recovery in China? Are you seeing any green shoots? Any specifics other than like an easier comp? Ram Krishnan: Ram here. Yes, we did not see any delays from customers. Certainly, nothing in the Middle East or North America or Europe. All of the project shipments that we had baked into our Q4 plan shift. So, we are not sensing any of that. And the capital cycle remains to be strong for us in energy, energy transition, power, LNG. So, the pace of business and process and hybrid continues. Obviously, the discrete recovery is what we're watching. Orders turning positive for our Discrete Automation business in Q4 is certainly a positive for us. And we're confident that Test & Measurement will see continued momentum going into 2025. And then what was your second piece of your question? Deane Dray: China. Yes, China. Ram Krishnan: In terms of China, obviously, the power segment in China is pretty good for us. It's really discrete and chemical recovery. Our hope is, obviously, there's a lot of stimulus. There's certainly some green shoots we're seeing in the chemical space we expect to manifest in the first half. it will come down, the pace of discrete recovery, which we're anticipating to happen in the second half of 2025. So, that kind of shapes up our China plan low to mid-single-digit growth for next year. Operator: Our next question comes from Nigel Coe from Wolfe Research. Please go ahead with your question. Nigel Coe: Lots to unpack here. That's for sure. So just on that last part, the DA kind of trends in the f”
Verify independently
SEC filings for EMR ↗ · Claim quote is verbatim from the 2024Q4 earnings call.